Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CMOP + chidamide
- Development stage
- Unknown
- Lead developer
- Akeso
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
CMOP + chidamide is a combination chemotherapy regimen consisting of the CMOP protocol (cyclophosphamide, mitoxantrone hydrochloride liposome, vincristine, and prednisone) together with chidamide. Chidamide is a selective benzamide class histone deacetylase (HDAC) inhibitor that targets subtypes 1, 2, 3 of class I HDAC and subtype 10 of class IIb HDAC. The combination aims to leverage the cytotoxic effects of standard chemotherapeutic agents in the CMOP regimen with the epigenetic modulation and pro-apoptotic activity provided by chidamide. This approach is being investigated for its potential to improve outcomes in hematologic malignancies such as lymphoma by inducing cell cycle arrest and apoptosis through both direct cytotoxicity and alteration of gene expression via HDAC inhibition[2][4].
- Brand names
- Duoenda
- Other names
- CMOP regimen plus chidamideCMOP+Chidamide
02
Targets
DNAGR (Glucocorticoid receptor)HDAC1 (Histone Deacetylase 1)HDAC10 (Histone Deacetylase 10)HDAC2 (Histone deacetylase 2)HDAC3 (Histone Deacetylase 3)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on CMOP + chidamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CMOP + chidamide.